Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients.
Walczak P, Choquet S, Dantal J, Boutboul D, Suarez F, Baron M, Morel V, Cluzeau T, Touati M, Elias M, Bachy E, Nicolas-Virelizier E, Houot R, Venton G, Jacquet C, Moles-Moreau MP, Jardin F, Durot E, Balegroune N, Ecotiere L, Guieze R, Kamar N, Ysebaert L, Couzi L, Gonzalez H, Roulin L, Ou K, Caillard S, Zimmermann H, Trappe RU, Roos-Weil D. Walczak P, et al. Among authors: morel v. Haematologica. 2023 Oct 1;108(10):2814-2819. doi: 10.3324/haematol.2022.282297. Haematologica. 2023. PMID: 36891749 Free PMC article. No abstract available.
CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes.
Lacan C, Caron J, Tarantino N, Fouquet B, Cherai M, Parizot C, Morel V, Souchet L, Uzunov M, Gorochov G, Nguyen-Quoc S, Sourdeau E, Vieillard V, Miyara M, Vinit A, Solorzano S, Soussain C, Houillier C, Metz C, Autran B, Litvinova E, Le Garff-Tavernier M, Norol F, Roos-Weil D, Choquet S, Guihot A, Baron M. Lacan C, et al. Among authors: morel v. Haematologica. 2023 Dec 1;108(12):3485-3490. doi: 10.3324/haematol.2023.282875. Haematologica. 2023. PMID: 37345469 Free PMC article. No abstract available.
Circulating tumor cells in Waldenström macroglobulinemia.
Boccon-Gibod C, Sourdeau E, Morel P, Chapiro E, Nguyen-Khac F, Bravetti C, Davi F, Morel V, Gauthier N, Grenier A, Boussen I, Choquet S, Leblond V, Le Garff-Tavernier M, Baron M, Roos-Weil D. Boccon-Gibod C, et al. Among authors: morel v. Leukemia. 2024 Apr;38(4):903-907. doi: 10.1038/s41375-024-02156-3. Epub 2024 Feb 9. Leukemia. 2024. PMID: 38332185 No abstract available.
CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network.
Choquet S, Soussain C, Azar N, Morel V, Metz C, Ursu R, Waultier-Rascalou A, di Blasi R, Houot R, Souchet L, Roos-Weil D, Uzunov M, Quoc SN, Jacque N, Boussen I, Gauthier N, Ouzegdouh M, Blonski M, Campidelli A, Ahle G, Guffroy B, Willems L, Corvilain E, Barrie M, Alcantara M, le Garff-Tavernier M, Psimaras D, Weiss N, Baron M, Bravetti C, Hoang-Xuan K, Davi F, Shor N, Alentorn A, Houillier C. Choquet S, et al. Among authors: morel v. Am J Hematol. 2024 Apr 8. doi: 10.1002/ajh.27316. Online ahead of print. Am J Hematol. 2024. PMID: 38586986
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Talbot A, Bobin A, Tabone L, Lambert J, Boccaccio C, Deal C, Petillon MO, Allangba O, Agape P, Arnautou P, Belkhir R, Cailleres S, Chaoui D, Chrétien ML, Decaux O, Schulmann S, Frenzel L, Gastaud L, Huart A, Hulin C, Karlin L, Laribi K, Le Calloch R, Lenain P, Macro M, Manier S, Montes L, Moreau S, Moreau P, Morel V, Norwood J, Piocelle FO, Perrot A, Pica GM, Rey P, Schmitt A, Stoppa AM, Tiab M, Touzeau C, Vidal V, Vignon M, Vincent L, Van De Wyngaert Z, Zarnitsky C, Kerbouche N, Paka P, Leleu X, Arnulf B, Avet-Loiseau H, Du Myélome IIF. Talbot A, et al. Among authors: morel v. Haematologica. 2023 Oct 1;108(10):2774-2782. doi: 10.3324/haematol.2022.281772. Haematologica. 2023. PMID: 37078253 Free PMC article.
On behalf of the SFGM-TC: Real-life use of third-party virus-specific T-cell transfer in immunocompromised transplanted patients.
Leroyer EH, Petitpain N, Morisset S, Neven B, Castelle M, Winter S, Souchet L, Morel V, Le Cann M, Fahd M, Yacouben K, Mechinaud F, Ouachée-Chardin M, Renard C, Wallet HL, Angoso M, Jubert C, Chevallier P, Léger A, Rialland F, Dhedin N, Robin C, Maury S, Beckerich F, Beauvais D, Cluzeau T, Loschi M, Fernster A, Bittencourt MC, Cravat M, Bilger K, Clément L, Decot V, Gauthier M, Legendre A, Larghero J, Ouedrani A, Martin-Blondel G, Pochon C, Reppel L, Rouard H, Nguyen-Quoc S, Dalle JH, D'Aveni M, Bensoussan D. Leroyer EH, et al. Among authors: morel v. Hemasphere. 2024 Jan 27;8(1):e40. doi: 10.1002/hem3.40. eCollection 2024 Jan. Hemasphere. 2024. PMID: 38434523 Free PMC article. No abstract available.
Predictive Factors of Response to Immunotherapy in Lymphomas: A Multicentre Clinical Data Warehouse Study (PRONOSTIM).
Detroit M, Collier M, Beeker N, Willems L, Decroocq J, Deau-Fischer B, Vignon M, Birsen R, Moufle F, Leclaire C, Balladur E, Deschamps P, Chauchet A, Batista R, Limat S, Treluyer JM, Ricard L, Stocker N, Hermine O, Choquet S, Morel V, Metz C, Bouscary D, Kroemer M, Zerbit J. Detroit M, et al. Among authors: morel v. Cancers (Basel). 2023 Aug 9;15(16):4028. doi: 10.3390/cancers15164028. Cancers (Basel). 2023. PMID: 37627056 Free PMC article.
Initial experience, feasibility, and technical development with an electromagnetic navigation assistance in percutaneous pelvic bone cementoplasty: retrospective analysis.
Boeken T, Pouliquen G, Premat K, Benac B, Shotar E, Cormier É, Talbi A, Bonaccorsi R, Morardet L, Morel V, Spano JP, Pascal-Mousselard H, Chiras J, Clarençon F. Boeken T, et al. Among authors: morel v. Eur Radiol. 2023 Apr;33(4):2605-2611. doi: 10.1007/s00330-022-09252-x. Epub 2022 Nov 15. Eur Radiol. 2023. PMID: 36378253
156 results